We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medicsight | LSE:MDST | London | Ordinary Share | GB00B1YD4B09 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.45 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
31/3/2010 11:05 | I got some yesterday @ 5.16 and 5.11. the 5.11 did not shown on the system. CASH £10.5M, enough to last for up to 2 years. | rejawna | |
29/1/2010 20:59 | Errr..... because they have a tendancy to lose plenty of it each year. | the big fella | |
29/1/2010 20:21 | Why would you not buy as significantly below cash????????????? | red army | |
29/1/2010 17:09 | Who are house-broker? I'll continue to watch here. Might be a good chance to make some money! | stuart14 | |
29/1/2010 16:34 | There has been a determined seller all week in big volume,what troubles me is why KBC have suddenly dropped their price by 35%. | mikeja | |
29/1/2010 16:31 | There isn't any volume so I guess nothing too sinister. MM's are getting nervous across AIM now, they are less and less prepared to hold stock. | stuart14 | |
29/1/2010 16:21 | Definitely,KBC on the offer at 3.75,smells really bad.Has the cash disappeared into thin air? | mikeja | |
29/1/2010 16:08 | Hmmm. Somethings afoot! | stuart14 | |
29/1/2010 16:05 | I met someone recently who worked for them. He was made redundant along with most of the Sale team and Dev team I believe. | stuart14 | |
29/1/2010 15:02 | On the face of it they are cheap. However I have followed these since the old Radical Tech days on OFEX, and lets face it they have never failed to disappoint. | the big fella | |
29/1/2010 13:10 | Edison put a NPV of £147m on the co a year ago but were expecting permissions by H1 2009.The current mkt cap is £8m and cash around £10m | mikeja | |
29/1/2010 13:00 | Stuart,I guess they will roll it out themselves,all the machines are in place. How do you know they made redundancies b4 Xmas? | mikeja | |
29/1/2010 09:34 | I know they made a lot of redundancies before Christmas so overheads must be a lot lower now. I'd guess they'll get approval from the US or Japan and then look to sell up. What sort of price could they get? | stuart14 | |
28/1/2010 07:21 | At 6p they are valued at a discount to the cash and have tax losses of around £40m.Something may come out of Japan next month.If and when they get approval in both mkts,Edison has suggested they cld make £40m in the first yr,we will see,but it sure has been a long wait. | mikeja | |
26/1/2010 14:39 | This is why - not sure why it's taken them 3 weeks to tell the market? Additional Information request for FDA 510(k) Clearance of ColonCAD software Medicsight PLC (AIM: MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists radiologists in the early detection of disease, announces that on 5 January 2010 it received a further request for Additional Information (AI) letter from the US Food and Drug Administration (FDA) relating to the Company's currently pending 510(k) pre-market notification for the ColonCAD API 3.1 product. | spectoacc | |
26/1/2010 14:31 | This is surely becomming very very cheap now. | stuart14 | |
17/11/2009 12:23 | Hoodless Brennan comment; Medicsight (MDST, £17.9m), the Computer Aided Detection (CAD) and image analysis software business, reports Q3 results to 30 September 2009. Net revenues from external customers up 65% to £0.094m (Q309: £0.057m) and operating losses before interest and taxes are reduced to £6.6m (Q308: -£7.3m). The business is debt-free, with net cash of £12.3m (H109: £13.7m) at the end of September 2009. The group continues to reduce spend to preserve cash. Medicsight is still waiting for approval from the FDA and Japanese Ministry of Health, Labour and Welfare ("MHLW"). We are slightly concerned that the approvals are taking longer than usual. However, the strong balance sheet combined with the potential for FDA approval encourages us to retain our SPECULATIVE BUY. | philjeans | |
08/11/2009 04:34 | Thanks a lot Damanko! Looks like a lot has happened over the years. I'll dig thru my paperwork and see what i can come up with lol. Thanks again. ST | shortermer | |
31/10/2009 14:53 | Cheers for That damanko, More murkier than i had thought. I nearly got sucked into buying after reading Fryern's thread on Unq, entitled "Do you want to be a Millionaire" or something like. Thankfully I do not and a profit is all i hope for out of shares ;-). regards. | tenapen | |
30/10/2009 16:44 | Sorry but is this the old Radical Technology, from OFEX years ago, that underwent a reverse takeover or something? Newbies probably wouldn't recall but any long term shareholders here? Long term as in peeps who have held for over 4 years or so? Thanks, ST | shortermer | |
29/10/2009 20:40 | This forgotten crock could just turn out to be the nuggett at the bottom of the bucket. | philjeans | |
29/10/2009 20:11 | The '2009 European CT Colonography Company of the Year Award,' is presented to Medicsight for its exceptional performance demonstrated by the company's ColonCAD™, in the CT colonography [CTC] segment. With its decade long experience, Medicsight is an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and identification of colorectal disease. Originally, the company functioned as a R&D organisation, however over the last 2-3 years Medicsight has moved its focus to a more commercial nature by bringing the best of its products to market. The World Health Organisation (WHO) indicates that lung and colorectal cancers are one of the most prevalent cancers in western societies, and having had its cohesive focus on the CTC segment, Medicsight focused on the opportunities that were created in this space. With only one segment in its vicinity, Medicsight had significant resources to innovate and launch quality products under this category. As a result, Medicsight developed ColonCAD™, a leading software tool that improves the detection capabilities of CT colonography by meliorating the sensitivity and productivity of detecting polyps in the colon. | foret | |
29/10/2009 19:53 | Medicsight receives Frost & Sullivan Award | foret | |
28/10/2009 09:37 | Excellent news today from an independent survey in the US. Will add credibility to the product. | philjeans |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions